BR112017013521A2 - terapia de antagonista do receptor de oxitocina na fase luteal para implantação e gravidez em mulheres sob tecnologias reprodutivas assistidas - Google Patents

terapia de antagonista do receptor de oxitocina na fase luteal para implantação e gravidez em mulheres sob tecnologias reprodutivas assistidas

Info

Publication number
BR112017013521A2
BR112017013521A2 BR112017013521-3A BR112017013521A BR112017013521A2 BR 112017013521 A2 BR112017013521 A2 BR 112017013521A2 BR 112017013521 A BR112017013521 A BR 112017013521A BR 112017013521 A2 BR112017013521 A2 BR 112017013521A2
Authority
BR
Brazil
Prior art keywords
implantation
receptor antagonist
pregnancy
luteal
increasing
Prior art date
Application number
BR112017013521-3A
Other languages
English (en)
Inventor
Arce Joan-Carles
Original Assignee
Ferring B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring B.V. filed Critical Ferring B.V.
Publication of BR112017013521A2 publication Critical patent/BR112017013521A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/42—Gynaecological or obstetrical instruments or methods
    • A61B17/425—Gynaecological or obstetrical instruments or methods for reproduction or fertilisation
    • A61B17/435—Gynaecological or obstetrical instruments or methods for reproduction or fertilisation for embryo or ova transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)

Abstract

a presente invenção se refere à utilização de um antagonista do receptor de oxitocina em fêmeas submetidas à transferência de embriões como parte de uma tecnologia de reprodução assistida. em particular, são fornecidos métodos para aumentar a taxa de implantação contínua, aumentar a taxa de gravidez contínua, aumentar a taxa de gravidez clínica e / ou aumentar a taxa de natalidade viva em uma pessoa do sexo feminino submetida à transferência de embriões. especificamente, os antagonistas são liberados na fase lútea quando o endométrio é receptivo à implantação de embriões e / ou quando o embrião atingiu o estágio de blastocisto.
BR112017013521-3A 2014-12-22 2015-12-21 terapia de antagonista do receptor de oxitocina na fase luteal para implantação e gravidez em mulheres sob tecnologias reprodutivas assistidas BR112017013521A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14199709.8 2014-12-22
EP14199709.8A EP3037101B1 (en) 2014-12-22 2014-12-22 Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies
US14/643,307 2015-03-10
US14/643,307 US9579305B2 (en) 2014-12-22 2015-03-10 Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies
PCT/NL2015/050893 WO2016105190A1 (en) 2014-12-22 2015-12-21 Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies

Publications (1)

Publication Number Publication Date
BR112017013521A2 true BR112017013521A2 (pt) 2018-03-06

Family

ID=52338895

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017013521-3A BR112017013521A2 (pt) 2014-12-22 2015-12-21 terapia de antagonista do receptor de oxitocina na fase luteal para implantação e gravidez em mulheres sob tecnologias reprodutivas assistidas

Country Status (21)

Country Link
US (4) US9579305B2 (pt)
EP (2) EP3501533A1 (pt)
JP (2) JP6858130B2 (pt)
KR (1) KR20170135821A (pt)
CN (2) CN113940990A (pt)
AU (1) AU2015367900B2 (pt)
BR (1) BR112017013521A2 (pt)
CA (1) CA2971846A1 (pt)
CL (1) CL2017001640A1 (pt)
EA (1) EA201791361A1 (pt)
ES (1) ES2716862T3 (pt)
IL (1) IL253078B (pt)
MX (1) MX2017008455A (pt)
MY (1) MY181349A (pt)
PH (1) PH12017550030A1 (pt)
PL (1) PL3037101T3 (pt)
SG (1) SG11201705175RA (pt)
TW (1) TWI702043B (pt)
UA (1) UA125492C2 (pt)
WO (1) WO2016105190A1 (pt)
ZA (1) ZA201704958B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2845850A1 (en) 2013-09-10 2015-03-11 ObsEva S.A. Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists
EP2886107A1 (en) 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
UA122210C2 (uk) 2014-07-02 2020-10-12 Обсева С.А. Кристалічний о-метилоксим (3z,5s)-5-(гідроксиметил)-1-[(2'-метил-1,1'-біфеніл-4-іл)карбоніл]піролідин-3-oну, корисний у способах лікування станів, пов'язаних з активністю ot-r
EP3501533A1 (en) 2014-12-22 2019-06-26 Ferring B.V. Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies
AU2017205670B2 (en) 2016-01-04 2021-05-20 Merck Serono S.A. L-valinate of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
CA3031252A1 (en) * 2016-07-21 2018-01-25 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
EP4025207A1 (en) 2019-09-03 2022-07-13 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
US20230102503A1 (en) 2020-02-10 2023-03-30 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy
CN114292907A (zh) * 2020-12-15 2022-04-08 苏州亿康医学检验有限公司 用于反复植入失败的生物标志物和诊断与治疗方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9604341D0 (sv) * 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
AUPP421298A0 (en) 1998-06-19 1998-07-09 Fertilitescentrum Ab Method and medium for in vitro culture of human embryos
HUP0302632A2 (hu) * 2001-01-09 2003-11-28 Schering Ag Antigesztagének alkalmazása gyorsított endometriális érés gátlására meddőségi kezelés alatt
YU21104A (sh) * 2001-09-12 2006-08-17 Applied Research Systems Ars Holding N.V. Upotreba hcg i lh u kontrolisanoj hiperstimulaciji ovarijuma
EP1480998B1 (en) 2002-02-27 2006-11-22 Ferring BV Intermediates and methods for making heptapeptide oxytocin analogues
UA78058C2 (en) * 2002-07-05 2007-02-15 Applied Research Systems Pyrrolidine derivative as oxitocin antagonists
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
FR2849380A1 (fr) * 2002-12-27 2004-07-02 Ernest Loumaye NOUVELLE UTILISATION D'UN AGONISTE DU GnRH
US7111275B2 (en) 2003-08-28 2006-09-19 International Business Machines Corporation Electronic circuit design analysis system
EP1664003A1 (en) 2003-09-18 2006-06-07 Axys Pharmaceuticals, Inc. Haloalkyl containing compounds as cysteine protease inhibitors
MXPA06003158A (es) 2003-09-22 2006-06-05 Pfizer Derivados de triazol sustituidos como antagonistas de oxitocina.
EP1555029A1 (en) 2004-01-19 2005-07-20 Ferring B.V. Use of substances having oxytocin antagonistic properties for the preparation of a medicament for treating hypertension
KR100985449B1 (ko) * 2005-05-10 2010-10-05 페링 인터내셔널 센터 에스 에이 옥시톡신 및/또는 바소프레신 길항제의 용도
WO2010010201A1 (es) 2008-07-22 2010-01-28 Equipo Ivi Investigacion Sl Perfil de expresion genetica como marcador de la receptividad endometrial
AU2010246918A1 (en) 2009-05-14 2011-12-01 Adelaide Research & Innovation Pty Ltd Methods for the collection and maturation of oocytes
JP6186353B2 (ja) 2011-07-01 2017-08-23 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ヒト卵丘細胞の発生ステージを決定するための方法
US10271876B2 (en) 2011-11-23 2019-04-30 Mezadata Medical Ip Holding Llc Method of in vitro fertilization with delay of embryo transfer and use of peripheral blood mononuclear cells
WO2013181549A2 (en) 2012-05-31 2013-12-05 Auxogyn, Inc. In vitro embryo blastocyst prediction methods
EP2922475A1 (en) 2012-11-26 2015-09-30 Ferring BV Method and system for diagnosing uterine contraction levels using image analysis
EP3501533A1 (en) 2014-12-22 2019-06-26 Ferring B.V. Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies

Also Published As

Publication number Publication date
AU2015367900A1 (en) 2017-08-03
EP3037101B1 (en) 2019-03-06
ES2716862T3 (es) 2019-06-17
MY181349A (en) 2020-12-21
US10688106B2 (en) 2020-06-23
PH12017550030A1 (en) 2018-01-15
EP3501533A1 (en) 2019-06-26
KR20170135821A (ko) 2017-12-08
CA2971846A1 (en) 2016-06-30
EA201791361A1 (ru) 2017-11-30
ZA201704958B (en) 2019-10-30
IL253078A0 (en) 2017-08-31
US9579305B2 (en) 2017-02-28
UA125492C2 (uk) 2022-04-13
CL2017001640A1 (es) 2018-01-26
US20170348325A1 (en) 2017-12-07
JP6858130B2 (ja) 2021-04-14
US10183029B2 (en) 2019-01-22
CN107249618B (zh) 2021-11-16
JP7184935B2 (ja) 2022-12-06
US20160175283A1 (en) 2016-06-23
IL253078B (en) 2020-04-30
US20200352962A1 (en) 2020-11-12
US20170189415A1 (en) 2017-07-06
JP2018505212A (ja) 2018-02-22
WO2016105190A1 (en) 2016-06-30
TW201636016A (zh) 2016-10-16
AU2015367900B2 (en) 2021-05-13
US11752157B2 (en) 2023-09-12
JP2021054863A (ja) 2021-04-08
CN107249618A (zh) 2017-10-13
MX2017008455A (es) 2018-04-26
TWI702043B (zh) 2020-08-21
PL3037101T3 (pl) 2019-06-28
SG11201705175RA (en) 2017-07-28
NZ733869A (en) 2020-10-30
CN113940990A (zh) 2022-01-18
EP3037101A1 (en) 2016-06-29

Similar Documents

Publication Publication Date Title
BR112017013521A2 (pt) terapia de antagonista do receptor de oxitocina na fase luteal para implantação e gravidez em mulheres sob tecnologias reprodutivas assistidas
BR112018013074A2 (pt) terapias de célula efetora imune com eficácia real-çada
BR112018068126A2 (pt) sistemas e métodos para a produção e liberação de pasta fluida gelada medicinal
SI2951133T1 (sl) Geopolimerni vezivni sistem za ognjevzdržne lite predmete, serija suhih ognjevzdržnih litih predmetov in uporaba navedene serije
CL2017000053A1 (es) Anticuerpos de unión a protofibrillas aß
HK1243430A1 (zh) 通過施用il-6r拮抗劑治療乾眼病的方法
HUE040176T2 (hu) Elnyújtott, hosszantartó és folyamatos felszabadulású progeszteront tartalmazó méhnyakpesszárium koraszülés megelõzésére
BR102015009464A2 (pt) veículo
CO7111317A2 (es) Método para el tratamiento de enfermedades ginecológicas
HK1217442A1 (zh) 鹽用於治療非糖尿病哺乳動物的雌性不育症的用途
TWD179860S (zh) 插頭之部分
TWD181606S (zh) 插頭之部分
AR095834A1 (es) Forma de dosificación de un antagonista del receptor de progesterona, composición farmacéutica
EP3184052A4 (en) Cell collection pad for examining cervical diseases and collection kit comprising same
GB2547924B (en) Birthing device for assisting childbirth
IL250212A0 (en) Tungsten salts (vi) for use in the treatment of infertility, to favor normal fertility and reproduction in the female of non-diabetic mammals, as well as to improve the efficiency of assisted reproduction techniques
UA85636U (ru) Способ лечения угрозы преждевременных родов у беременных с многоплодной беременностью препаратом «спаскупрель»
TH180281A (th) การบำบัดของออกซีโตซินรีเซปเตอร์แอนตาโกนิสต์ในระยะหลังไข่ตก สำหรับการฝังตัวและการตั้งครรภ์ในผู้หญิงที่ได้รับเทคโนโลยีที่เกี่ยวกับ การสืบพันธุ์ที่ได้รับการช่วยเหลือ
CN302581118S (zh) 剔毛器
CN302562256S (zh) 拔毛器
GB201510890D0 (en) Side-reinforced, collapsible duck bill vaginal speculum and universal side reinforced glove for duck bill vagina speculum
UA91555U (uk) Спосіб діагностики фетоплацентарної недостатності в ранні терміни вагітності у вагітних з невиношуванням
ES1088204Y (es) Dispositivo para incrementar la sujecion del zapato al pie
UA78016U (ru) Способ диагностики внутриутробного состояния плода при плацентарной дисфункции в III триместре беременности
CN302437345S (zh) 鼻毛器(hp-309)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]